Sac-TMT is the first and only ADC globally to show an overall survival (OS) benefit compared with platinum doublet chemotherapy and be approved for advanced NSCLC that has progressed after only TKI ...
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $28.0, a high estimate of $34.00, and a low estimate of $16.00. Highlighting a 6.67% decrease, ...
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2025 AND KEY EVENTS DURING THE PERIOD Financial and corporate situation Operating deficit reduced by 24% compared ...
Innovative genetic engineering strategies are transforming crops, enabling them to withstand extreme climate conditions and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback